We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Highly Purified Menotropin (HP-hMG) Versus Recombinant FSH (rFSH) Plus Recombinant LH (rLH) in Intrauterine Insemination Cycles in Women ≥35 Years: a Prospective Randomized Trial.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01604044
Recruitment Status : Completed
First Posted : May 23, 2012
Last Update Posted : September 5, 2014
Information provided by (Responsible Party):

Study Description
Brief Summary:
This study evaluates the effects of different therapies in ovulation induction in Intrauterine Insemination Cycles.

Condition or disease Intervention/treatment Phase
Female Infertility Drug: Meropur 150 a day Drug: Gonal-f 150 plus Luveris 150 Phase 1

Study Design

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 579 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Study Start Date : May 2012
Primary Completion Date : September 2013
Study Completion Date : September 2013
Arms and Interventions

Arm Intervention/treatment
Active Comparator: HP-hMG Drug: Meropur 150 a day
one subcutaneous injection a day
Active Comparator: rFSH plus rLH Drug: Gonal-f 150 plus Luveris 150
one subcutaneous injection a day

Outcome Measures

Primary Outcome Measures :
  1. ongoing pregnancy rate [ Time Frame: 12 weeks ]

Secondary Outcome Measures :
  1. number of cancelled cycles for low or no response, the number of interrupted cycles for high risk of OHSS and multiple pregnancies [ Time Frame: 30 days ]

Other Outcome Measures:
  1. duration of stimulation, total gonadotropin dose, number of midsize follicles, dominant follicles, E2 levels, endometrial thickness on hCG day, Progesterone levels, endometrial thickness on the midluteal phase. [ Time Frame: 30 days ]

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   35 Years to 41 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • women with story of infertility sine causa and mild-moderate male factor
  • regular ovulatory menstrual cycles
  • BMI ≤27 kg/m2
  • normal day 3 hormonal pattern
  • bilateral tubal patency

Exclusion Criteria:

  • mono/bilateral tubal occlusion,
  • severe male factor
  • polycystic ovarian syndrome or any systemic disease or endocrine or metabolic abnormalities
  • pelvic inflammatory disease
  • endometriosis
  • sexual organ malformations
  • neoplasms or breast pathology incompatible with gonadotropin stimulation.
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01604044

Policlinico Agostino Gemelli
Rome, Italy, 00168
Sponsors and Collaborators
Catholic University of the Sacred Heart
More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Rosanna Apa, professor, Catholic University of the Sacred Heart
ClinicalTrials.gov Identifier: NCT01604044     History of Changes
Other Study ID Numbers: Meropur2009
First Posted: May 23, 2012    Key Record Dates
Last Update Posted: September 5, 2014
Last Verified: September 2014

Additional relevant MeSH terms:
Infertility, Female
Genital Diseases, Male
Genital Diseases, Female